Available evidence does not indicate that treatments approved for people with Alzheimer’s disease can improve cognitive function in people with Huntington’s disease, according to a review study. “The existing literature does not provide sufficient evidence to support the use of cholinesterase inhibitors or memantine for managing cognitive symptoms in…
uniQure’s experimental gene therapy AMT-130 safely and effectively slows the progression of Huntington’s disease, according to top-line, three-year data from two Phase 1/2 clinical trials. At 36 months, the use of high-dose AMT-130 was shown to slow Huntington’s progression by 75% — results the developer called “statistically significant”…
Three months of daily treatment with Skyhawk Therapeutics’ oral candidate SKY-0515 safely and effectively reduced blood levels of Huntington’s disease-associated proteins in people with the neurodegenerative condition. That’s according to interim results from a substudy of a Phase 1 clinical trial that specifically showed a greater reduction with…
Healthtech company Neuralight is teaming up with the CHDI Foundation to explore the possibility of monitoring eye movements as a method to track Huntington’s disease activity in clinical trials. The CHDI Foundation is a nonprofit biomedical research organization dedicated to advancing new therapies that can slow the…
Pridopidine may safely and effectively slow Huntington’s disease progression in patients who aren’t taking antidopaminergic medications, which are commonly used for psychiatric symptoms and chorea, or involuntary movements. That’s according to full results from the Phase 3 PROOF-HD clinical trial  (NCT04556656), which tested pridopidine against a…
A committee of the European Medicines Agency’s (EMA) has recommended that the experimental oral medication pridopidine not be approved for adults with Huntington’s disease. The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommendation will be reviewed by the European Commission, which has final say over therapy…
Participating in dance classes may help people with Huntington’s disease improve their balance and maintain their functional capacity, according to the results of a small U.S. pilot study in which patient mobility was assessed before and after an intervention program. The researchers shared the results in a talk titled…
Long-term care facilities can help people with Huntington’s disease thrive, and successfully managing the transition into long-term care requires cooperation and communication from everyone involved, social workers said. Caregivers need to pay attention to “indicators,” assessments of what a person can do without assistance — that can involve anything…
A number of observational studies meant to improve knowledge about Huntington’s disease — and aiming to inform clinical trials, generate data from patients of all ages, and help speed the development of new treatments — are now enrolling participants in the U.S. Several of these studies were described by…
Several treatments aiming to reduce levels of mutant huntingtin (mHTT), the protein that drives Huntington’s disease, are being tested in clinical trials or may soon enter clinical testing. Company representatives described those therapies in a luncheon session at the 40th annual Huntington’s Disease Society of America (HDSA) convention,…
Get regular updates to your inbox.
